Oliver Grimm

Oliver Grimm, PhD, currently serves as the Director of Discovery PKPD & QSP Modelling at Novo Nordisk, focusing on global drug discovery within research and early development since June 2023. Previously, Oliver Grimm held the position of Disease Modelling Leader in Clinical Pharmacology Oncology at Roche from 2013 to May 2023, where notable contributions included co-inventing a biopsy simulation platform, developing PBPK models for clinical trials, and managing collaborations while aligning with key stakeholders. Additionally, Oliver Grimm led a global team in the role of Head of Imaging Lab for Digital Pathology at Roche, focusing on digital pathology platforms and machine learning applications in early biomarker development. Prior to Roche, Oliver Grimm conducted postdoctoral research at Princeton University and Parc Cientific de Barcelona, specializing in mathematical modeling and computational analysis of biological systems. Oliver Grimm obtained a Ph.D. in Molecular Biology from the University of Cambridge and a Diplom in Cell Biology from Heidelberg University.